> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Expanding Covid Work with Aetion
- URL: https://www.fdaweb.com/fda-expanding-covid-work-with-aetion/
- Published: 2021-10-21T12:00:00.000Z
- Updated: 2026-09-14T17:19:50.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5150415

FDA is expanding its relationship with Aetion to use real-world evidence (RWE) to study Covid-19 interventions and advance regulatory science and innovation. Aetion [says](https://www.marketwatch.com/press-release/fda-selects-aetion-evidence-platform-to-advance-regulatory-science-and-innovation-2021-10-21?tesla=y&ref=fdaweb.com) the agency and company will use the Aetion evidence platform to develop a framework and system of studies for the rapid assessment of Covid-19 inpatient medical products.

“This project is designed to demonstrate how using a platform-based approach furthers regulatory learnings on the use of RWE to inform decision-making,” the company says. “The work will also provide a scalable infrastructure for the rapid development and evaluation of Covid-19 therapies, which can be applied for future public health emergencies.”

In a research collaboration announced 5/2020, FDA and Aetion explored the utility of real-world data (RWD) to advance the understanding of and response to Covid-19\. The two say they have developed mechanisms to assess data fitness for use; identified methodological good practices on working with RWD for Covid-19, and built the foundation for rapid-cycle analytics to address critical and emergent public health questions.